<DOC>
	<DOCNO>NCT01962948</DOCNO>
	<brief_summary>This phase I/II trial study side effect best dose ganetespib give together paclitaxel see well work treat patient recurrent ovarian , fallopian tube , primary peritoneal cancer . Drugs use chemotherapy , paclitaxel , work different way stop growth tumor cell , either kill cell stop dividing . Ganetespib may stop growth tumor cell block enzymes need cell growth . Giving paclitaxel ganetespib may effective treatment ovarian , fallopian tube , primary peritoneal cancer .</brief_summary>
	<brief_title>Paclitaxel Ganetespib Treating Patients With Recurrent Ovarian , Fallopian Tube , Primary Peritoneal Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine recommend Phase II dose ganetespib weekly paclitaxel . ( Phase I ) II . Probability survive progression-free least 6 month initiate therapy . ( Phase II ) III . Clinical response rate ( partial complete response define Response Evaluation Criteria Solid Tumors [ RECIST ] 1.1 criterion ) . ( Phase II ) SECONDARY OBJECTIVES : I . Determine nature degree toxicity ganetespib weekly paclitaxel cohort patient measure frequency severity adverse reaction . ( Phase I ) II . Determine nature degree toxicity ganetespib weekly paclitaxel cohort patient measure frequency severity adverse reaction encounter . ( Phase II ) III . Duration progression-free survival . ( Phase II ) OUTLINE : This phase I , dose-escalation study ganetespib follow phase II study . Patients receive paclitaxel intravenously ( IV ) 1 hour ganetespib IV 1 hour day 1 , 8 , 15 . Courses repeat every 28 day absence disease progression unacceptable toxicity . After completion study treatment , patient follow every 3 month 2 year , every 6 month 2 year , annually thereafter .</detailed_description>
	<mesh_term>Neoplasms , Glandular Epithelial</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Patients histologically cytologically confirm recurrent epithelial ovarian , fallopian tube primary peritoneal cancer receive two prior treatment regimens Patients must measurable disease , define least one lesion accurately measure least one dimension accordance RECIST criterion version ( v. ) 1.1 Patients must one prior platinumbased chemotherapeutic regimen management primary disease contain carboplatin , cisplatin , another organoplatinum compound ; initial treatment may include intraperitoneal therapy , highdose therapy , consolidation , extend therapy administer completion initial chemotherapy ; patient must consider platinum resistant refractory accord standard Gynecologic Oncology Group ( GOG ) criterion , i.e. , treatmentfree interval follow platinum le 12 month , persistent disease completion primary platinumbased therapy progress platinumbased therapy Eastern Cooperative Oncology Group ( ECOG ) performance status 0 2 Leukocytes &gt; = 3,000/mcL Absolute neutrophil count &gt; = 1,500/mcL Platelets &gt; = 100,000/mcL Total bilirubin = &lt; normal institutional limit Aspartate aminotransferase ( AST ) /alanine aminotransferase ( ALT ) ( serum glutamic oxaloacetic transaminase [ SGOT ] /serum glutamate pyruvate transaminase [ SGPT ] ) = &lt; 2 time institutional normal limit Creatinine = &lt; normal institutional limit OR Creatinine clearance &gt; = 60 Ml/min/1.73 m^2 patient creatinine level institutional normal Ability willingness comply schedule visit , treatment plan , laboratory assessment study procedure Ability understand willingness sign write informed consent Health Insurance Portability Accountability Act ( HIPAA ) consent document Patients surgery , chemotherapy radiotherapy within 4 week prior enter study toxicity recover = &lt; grade 1 adverse event due agent administer 4 week earlier ( exception alopecia ) ; patient may receive investigational agent Histologic diagnosis benign borderline tumor ( 'tumor low malignant potential ' ) malignant tumor nonepithelial origin ( germ cell tumor , sexcord stromal tumor ) ovary , fallopian tube peritoneum Patients know brain metastasis History allergic reaction Cremophor EL , paclitaxel component Prior history &gt; = grade 2 neurotoxicity toxicity require discontinuation taxane therapy resolve = &lt; grade 1 , exception alopecia Diagnosis another malignancy within two year first dose , previously treat another malignancy evidence residual disease , exception synchronous endometrial cancer ; carcinoma situ consider malignancy Uncontrolled intercurrent illness include , limited , ongoing active infection , know serious cardiac illness psychiatric illness/social situation would limit compliance study requirement ; know serious cardiac illness medical condition include , limited : History document congestive heart failure ( CHF ) , New York Heart Association ( NYHA ) class II/III/IV , history dyspnea , orthopnea , edema require current treatment angiotensinconverting enzyme ( ACE ) inhibitor , angiotensin II receptor blocker , beta blocker , diuretic NOTE : use medication treatment hypertension allow Screening QTc ( QT interval correct heart rate ) &gt; 470 msec history QT ( cardiac interval start Q wave end T wave ) prolongation take medication Highrisk uncontrolled arrhythmia ( ventricular arrhythmia , highgrade atrioventricular [ AV ] block , supraventricular arrhythmia adequately ratecontrolled ) Arrhythmias require current treatment follow antiarrhythmic drug : flecainide , moricizine , propafenone Current coronary artery disease history myocardial infarction , angioplasty , coronary bypass surgery within precede 6 month , angina pectoris symptomatic within precede 6 month Known human immunodeficiency virus ( HIV ) positive patient combination antiretroviral therapy ineligible Pregnant breast feeding</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>